Children’s Cancer Institute signs MoU with Peter Mac
July 21, 2015
Children’s Cancer Institute is delighted to announce the strengthening and formalisation of its relationship with Melbourne’s Peter MacCallum Cancer Centre through a Memorandum of Understanding (MoU) that specifies areas of collaboration in cancer research for children and adolescents.
Each a leading translational cancer research enterprise in its own right, Children’s Cancer Institute and Peter Mac hope to leverage their combined expertise in ways that will benefit both.
The collaboration has multiple specific aims which include: advancing clinically relevant model systems; identifying, analysing and targeting key molecular drivers of cancer; establishing the infrastructure and streamlined processes necessary for delivering personalised medicine programs; strengthening research effort in cancer immunology; and putting in place the necessary information and communications technologies and expertise.
“We envisage that this MoU will stimulate a rigorous process of engagement across both institutions that will accelerate scientific discovery and clinical implementation,” said Children’s Cancer Institute Executive Director, Professor Michelle Haber.
“As part of the alliance, we will be establishing joint investments in programs and staff. That will help both organisations avoid duplication, not to mention a lot of wasted time and effort.
“We are all immensely optimistic about our joint capacity to drive improvements in health outcomes for children and adolescents with cancer – not only in Australia, but around the world.”
The Memorandum of Understanding was signed in early July by Professor Haber and Dale Fisher, Chief Executive of Peter MacCallum Cancer Centre.
About Children’s Cancer Institute
Originally founded by two fathers of children with cancer in 1976, Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. Forty years on, our vision remains unchanged – to save the lives of all children with cancer and to eliminate their suffering. The Institute has grown to now employ more than 220 researchers, operational staff and students, and has established a national and international reputation for scientific excellence.
Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments which can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimise side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life.
We are currently leading the establishment of the Zero Childhood Cancer national child cancer personalised medicine program for children with the most aggressive cancers, in partnership with the Sydney Children’s Hospitals Network. This program will revolutionise the way treatment decisions are made, with the aim of improving survivorship for those children at highest risk of treatment failure from their disease.